# Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma

> **NCT00017290** · PHASE3 · UNKNOWN · sponsor: **Genitope Corporation**

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** autologous immunoglobulin idiotype-KLH conjugate vaccine
- **BIOLOGICAL:** keyhole limpet hemocyanin
- **BIOLOGICAL:** sargramostim
- **DRUG:** cyclophosphamide
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate

## Key facts

- **NCT ID:** NCT00017290
- **Lead sponsor:** Genitope Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2000-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00017290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00017290, "Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00017290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*